US2009054631A1PendingUtilityA1

Compositions and methods for treatment of non-hodgkin's lymphoma

67
Assignee: GENENTECH INCPriority: Jul 2, 2004Filed: Jun 13, 2008Published: Feb 26, 2009
Est. expiryJul 2, 2024(expired)· nominal 20-yr term from priority
Inventors:Avi AshkenaziDylan L. DanielTheresa Shek
C12Q 2600/136C12Q 1/6886A61P 35/00C07K 16/3061C12Q 2600/106C12Q 2600/158G01N 2500/10G01N 33/57557A61K 39/395C07K 16/24
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to compositions of matter useful for the treatment of non-Hodgkin's lymphoma in mammals and to methods of using those compositions for the same.

Claims

exact text as granted — not AI-modified
1 . An antibody that binds to UNQ733 polypeptide, wherein the antibody:
 (a) is produced by a hybridoma having ATCC deposit no. PTA-6026, PTA-6027, PTA-6028, PTA-6029, PTA-6030, PTA-6031, PTA-6032, PTA-6033, PTA-6034, or progeny thereof;   (b) binds to the same epitope on UNQ733 polypeptide as an antibody produced by a hybridoma having ATCC deposit no. PTA-6026, PTA-6027, PTA-6028, PTA-6029, PTA-6030, PTA-6031, PTA-6032, PTA-6033 or PTA-6034; or   (c) competes with an antibody produced by a hybridoma having ATCC deposit no. PTA-6026, PTA-6027, PTA-6028, PTA-6029, PTA-6030, PTA-6031, PTA-6032, PTA-6033 or PTA-6034 for binding to UNQ733 polypeptide.   
     
     
         2 . The antibody of  claim 1 , wherein the antibody is conjugated to a growth inhibitory agent or cytotoxic agent. 
     
     
         3 . A fragment of the antibody of  claim 1  comprising an antigen binding region. 
     
     
         4 . A humanized form of the antibody of  claim 1 .

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.